Display Settings:

Format

Send to:

Choose Destination
J Alzheimers Dis. 2009;17(2):337-41. doi: 10.3233/JAD-2009-1051.

Brain-derived neurotrophic factor levels in Alzheimer's disease.

Author information

  • 1Texas Tech University Health Science Center, Department of Neurology, 3601 4th St. STOP 8321, Lubbock, TX 79430, USA. sid.obryant@ttuhsc.edu

Abstract

The current search for biomarkers that are diagnostic and/or prognostic of Alzheimer's disease (AD) is of vital importance given the rapidly aging population. It was recently reported that brain-derived neurotrophic factor (BDNF) fluctuated according to AD severity, suggesting that BDNF might have utility for diagnostics and monitoring of therapeutic efficacy. The current study sought to examine whether BDNF levels varied according to AD severity, as previously reported. There were 196 participants (Probable AD, n = 98; Controls, n = 98) in the Texas Alzheimer's Research Consortium (TARC) Longitudinal Research Cohort available for analysis. BDNF levels were assayed via multiplex immunoassay. Regression analyses were utilized to examine the relation between BDNF levels, Mini-Mental Status Examination, and Clinical Dementia Rating scores adjusting for age and gender. In adjusted models, BDNF levels did not distinguish between AD patients and normal controls and did not significantly predict AD severity or global cognitive functioning. In conclusion, these findings do not support the notion that BDNF serves as a diagnostic marker for AD or disease severity. It is likely that the most accurate approach to identifying biomarkers of AD will be through an algorithmic approach that combines multiple markers reflective of various pathways.

PMID:
19363274
[PubMed - indexed for MEDLINE]
PMCID:
PMC2787708
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for IOS Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk